Peptides: FDA urged to overrule advisory panel - Center for Science in the Public Interest

The Center for Science in the Public Interest urges the FDA to overrule its Pharmacy Compounding Advisory Committee's recommendation to include six peptides on the 503A Bulks List due to safety concerns and conflicts of interest among new committee members. This move threatens to undermine FDA's drug approval standards and public trust.

This Wire brief sits within Fusion42's coverage of Health.